Abyssinia Biosciences Partners with Cordance Medical to Enhance Alzheimer’s Treatment with Focused Ultrasound

Exciting Collaboration to Combat Alzheimer’s Disease

Abyssinia Biosciences and Cordance Medical have officially announced a groundbreaking partnership aimed at leveraging focused ultrasound technology to improve diagnostic and therapeutic approaches for Alzheimer’s disease. This collaboration focuses particularly on detecting toxic amyloid beta aggregations early on, which are closely linked to the progression of Alzheimer’s.

The Cutting-Edge Technologies Involved

Cordance Medical's innovative SonoBiopsy™ technology will play a pivotal role in this research, allowing for non-invasive early identification of toxic amyloid abnormalities. Furthermore, another technology called SonoScript™ is set to investigate the potential enhancement of brain biodistribution of Abyssinia's antibodies through the application of focused ultrasound.

Bhaskar Ramamurthy, the CEO and co-founder of Cordance Medical, shares insights on this new approach: “Ultrasound-guided drug delivery is an emerging method to improve the efficacy and safety of Aβ immunotherapy. In addition to its potential for obtaining liquid biopsies from the brain tissue non-invasively, focused ultrasound should be considered as one of the safest methods for monoclonal antibody delivery to targeted areas of the brain affected by disease.” This perspective supports the notion that focused ultrasound could be particularly groundbreaking in managing Alzheimer’s disease and enhancing treatment options for patience.

Focus on Prevention and Early Treatment

Frederic Godderis, co-founder and CEO of Abyssinia Biosciences, emphasizes the urgency of prevention and early treatment strategies. “Now that Aβ immunotherapy has been established as an effective strategy to slow cognitive decline in mild to moderate stages of Alzheimer’s disease, the focus shifts towards treating the earliest stages,” he states. The collaboration is set to evaluate how higher doses of Abyssinia's therapeutic antibodies can perform in preclinical models of Alzheimer’s, seeking to explore the potential of blood-brain barrier (BBB) opening for biomarker development.

About the Companies Involved

Abyssinia Biosciences

Abyssinia Biosciences, Inc. is a preclinical biotech company dedicated to developing drugs and vaccines targeting Alzheimer’s disease. The firm is notably concentrating on targeting toxic misfolded proteins in the brain, particularly toxic amyloid beta aggregates (oligomers). With promising preclinical data, Abyssinia aims to develop an oligomer-specific biomarker test, providing more effective blood-based diagnostics for Alzheimer's than currently available tests. The company is preparing to start its IND enabling studies within the year.

Cordance Medical

Cordance Medical, also in its preclinical stage, focuses on advancing patient care in brain diseases through its NeuroAccess platform. The ability to non-invasively open the blood-brain barrier holds tremendous potential for revolutionizing drug delivery and facilitating liquid biopsies, thus offering renewed hope for treating neurological conditions.

Looking Ahead

As these two innovative companies collaborate, the future of Alzheimer’s diagnostics and therapy seems promising. The potential integration of focused ultrasound technology with advanced antibody therapies could significantly enhance how we approach the treatment of this challenging disease. The partnership stands as a testament to the power of innovation, collaboration, and the shared goal of improving patient outcomes in the realm of Alzheimer’s disease.